Clinical Trial Update: PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of HCC [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating a PD-1 monoclonal antibody, lenvatinib, and transarterial chemoembolization (TACE) for non-resectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Lenvatinib (lenvatinib)
• PD-1 monoclonal antibody
• Transarterial chemoembolization (TACE)

Snippet

Sponsor: Tianjin Medical University Cancer Institute and Hospital | Conditions: Hepatocellular Carcinoma Non-resectable | Phase 2 | Status: UNKNOWN